The discussion will look at the advantages and disadvantages of engaging with Big Pharma, and then look at what can attract Big Pharma to new territories. Our conclusions will be used to reflect broadly on what this may mean for the microbiome field.
Big Pharma are experts at making a business out of commercialising small- molecule therapeutics, including the calculation of associated risks. What could motivate them to leave this comfort zone and embrace the unknown? Adalimumab (Humira®) is a good motivation. In quarter-one 2020, AbbVie reported a US net revenue of $3.7 billion from sales of this human-monoclonal- antibody. Although not without their specific challenges, the development of therapeutic-antibody technologies is now fully embraced by Big Pharma. So, how do emerging technologies breakthrough the “small-molecule barrier” in a similar manner?
Emerging therapeutic technologies present an array of exiting opportunities. For example, the therapeutic-microbiome field. Currently not dominated by Big Pharma, we see many innovative SMEs dominating; all focused on driving the development of a small pipeline of bio-therapeutics. This has resulted in an impressive range of innovative products in development, often targeting conditions for which conventional “small molecule” drug discovery projects have failed to adequately address. In 2018 we saw the first acquisition of a microbiome company by Big Pharma (purchase of Rebiotix by Ferring). However, most Big Pharma are more tentatively venturing into the microbiome field via collaborations (e.g. MSD and 4D Pharma, Takeda and Finch).
Craig Thomson will be chairing a discussion between Dr Andrew Wells and Dr Alex Therien, Executive Director and Head of Investigational Biology at Merck’s Exploratory Science Center (ESC), who both have direct experience of what Big Pharma look for in emerging technologies.
Craig Thomson, Dr Andrew Wells and Dr Alex Therien
You may also like
Plausibility, polymorphs and purity
Plausibility, polymorphs and purity have been recurring themes in the EPO’s Board of Appeal decisions. These topics can underpin a pharmaceutical company’s filing and life cycle management strategy. The EPO’s decisions have been mixed and, in the last year, the Boards have yet again pronounced on these topics in a number of decisions. We will review and discuss the key features of these decisions.
The power of bioinformatics: a focus on capturing bioinformatics innovation as part of an IP strategy
Thursday 18th March
We will look at patent trends in bioinformatics along with some real life case studies in order to see how companies have successfully protected bioinformatics innovations in areas including computational neuroscience, DNA Sequencing and remote healthcare monitoring.
‘Strengthening your core’ – embedding a healthy risk management framework within the core of your business
Thursday 4th March
This session will look at a number of simple steps that can be taken to implement a healthy risk management framework within the core of a healthcare business – aimed at strengthening team culture and behavioural norms.